vs

Side-by-side financial comparison of Identiv, Inc. (INVE) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Identiv, Inc. is the larger business by last-quarter revenue ($6.2M vs $3.8M, roughly 1.6× Vivos Therapeutics, Inc.). Identiv, Inc. runs the higher net margin — -60.3% vs -180.3%, a 119.9% gap on every dollar of revenue. On growth, Vivos Therapeutics, Inc. posted the faster year-over-year revenue change (3.4% vs -7.9%). Identiv, Inc. produced more free cash flow last quarter ($2.8M vs $-5.3M). Over the past eight quarters, Vivos Therapeutics, Inc.'s revenue compounded faster (5.8% CAGR vs -3.8%).

Identiv is a publicly traded Internet of Things technology company listed on the Nasdaq stock market.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

INVE vs VVOS — Head-to-Head

Bigger by revenue
INVE
INVE
1.6× larger
INVE
$6.2M
$3.8M
VVOS
Growing faster (revenue YoY)
VVOS
VVOS
+11.3% gap
VVOS
3.4%
-7.9%
INVE
Higher net margin
INVE
INVE
119.9% more per $
INVE
-60.3%
-180.3%
VVOS
More free cash flow
INVE
INVE
$8.2M more FCF
INVE
$2.8M
$-5.3M
VVOS
Faster 2-yr revenue CAGR
VVOS
VVOS
Annualised
VVOS
5.8%
-3.8%
INVE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INVE
INVE
VVOS
VVOS
Revenue
$6.2M
$3.8M
Net Profit
$-3.7M
$-6.9M
Gross Margin
18.1%
78.1%
Operating Margin
-76.4%
-166.8%
Net Margin
-60.3%
-180.3%
Revenue YoY
-7.9%
3.4%
Net Profit YoY
-948.2%
-143.8%
EPS (diluted)
$-0.17
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INVE
INVE
VVOS
VVOS
Q4 25
$6.2M
$3.8M
Q3 25
$5.0M
$6.8M
Q2 25
$5.0M
$3.8M
Q1 25
$5.3M
$3.0M
Q4 24
$6.7M
$3.7M
Q3 24
$6.5M
$3.9M
Q2 24
$6.7M
$4.1M
Q1 24
$6.7M
$3.4M
Net Profit
INVE
INVE
VVOS
VVOS
Q4 25
$-3.7M
$-6.9M
Q3 25
$-3.5M
$-5.4M
Q2 25
$-6.0M
$-5.0M
Q1 25
$-4.8M
$-3.9M
Q4 24
$-355.0K
$-2.8M
Q3 24
$85.9M
$-2.6M
Q2 24
$-6.2M
$-1.9M
Q1 24
$-4.6M
$-3.8M
Gross Margin
INVE
INVE
VVOS
VVOS
Q4 25
18.1%
78.1%
Q3 25
10.7%
58.0%
Q2 25
-9.4%
55.2%
Q1 25
2.5%
50.0%
Q4 24
-14.9%
56.7%
Q3 24
3.6%
60.5%
Q2 24
9.1%
65.4%
Q1 24
7.3%
56.7%
Operating Margin
INVE
INVE
VVOS
VVOS
Q4 25
-76.4%
-166.8%
Q3 25
-111.4%
-69.8%
Q2 25
-126.7%
-127.4%
Q1 25
-103.8%
-129.9%
Q4 24
-98.9%
-75.9%
Q3 24
-146.2%
-68.5%
Q2 24
-99.7%
-47.8%
Q1 24
-76.0%
-110.7%
Net Margin
INVE
INVE
VVOS
VVOS
Q4 25
-60.3%
-180.3%
Q3 25
-68.9%
-79.6%
Q2 25
-119.9%
-131.2%
Q1 25
-90.9%
-128.1%
Q4 24
-5.3%
-76.4%
Q3 24
1315.8%
-67.8%
Q2 24
-92.2%
-47.6%
Q1 24
-68.5%
-110.1%
EPS (diluted)
INVE
INVE
VVOS
VVOS
Q4 25
$-0.17
$-0.58
Q3 25
$-0.15
$-0.49
Q2 25
$-0.26
$-0.55
Q1 25
$-0.21
$-0.45
Q4 24
$0.00
$0.41
Q3 24
$3.62
$-0.40
Q2 24
$-0.27
$-0.60
Q1 24
$-0.21
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INVE
INVE
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$128.6M
$2.0M
Total DebtLower is stronger
$2.9M
Stockholders' EquityBook value
$140.7M
$-1.5M
Total Assets
$151.3M
$25.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INVE
INVE
VVOS
VVOS
Q4 25
$128.6M
$2.0M
Q3 25
$126.3M
$3.1M
Q2 25
$129.3M
$4.4M
Q1 25
$132.4M
$2.3M
Q4 24
$135.6M
$6.3M
Q3 24
$145.4M
$6.3M
Q2 24
$18.4M
$6.9M
Q1 24
$21.6M
$2.6M
Total Debt
INVE
INVE
VVOS
VVOS
Q4 25
$2.9M
Q3 25
Q2 25
Q1 25
Q4 24
$1.2M
Q3 24
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
INVE
INVE
VVOS
VVOS
Q4 25
$140.7M
$-1.5M
Q3 25
$143.7M
$2.5M
Q2 25
$146.4M
$4.6M
Q1 25
$150.5M
$4.4M
Q4 24
$154.1M
$8.0M
Q3 24
$156.7M
$7.7M
Q2 24
$65.1M
$6.3M
Q1 24
$70.2M
$582.0K
Total Assets
INVE
INVE
VVOS
VVOS
Q4 25
$151.3M
$25.2M
Q3 25
$151.0M
$25.6M
Q2 25
$153.9M
$26.0M
Q1 25
$158.7M
$11.3M
Q4 24
$163.2M
$15.3M
Q3 24
$177.0M
$15.3M
Q2 24
$97.8M
$15.8M
Q1 24
$101.8M
$11.8M
Debt / Equity
INVE
INVE
VVOS
VVOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INVE
INVE
VVOS
VVOS
Operating Cash FlowLast quarter
$3.0M
$-3.8M
Free Cash FlowOCF − Capex
$2.8M
$-5.3M
FCF MarginFCF / Revenue
45.8%
-139.7%
Capex IntensityCapex / Revenue
3.3%
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INVE
INVE
VVOS
VVOS
Q4 25
$3.0M
$-3.8M
Q3 25
$-2.9M
$-4.2M
Q2 25
$-3.6M
$-3.5M
Q1 25
$-3.3M
$-3.8M
Q4 24
$-5.9M
$-2.9M
Q3 24
$-7.2M
$-4.2M
Q2 24
$-993.0K
$-3.0M
Q1 24
$-1.3M
$-2.5M
Free Cash Flow
INVE
INVE
VVOS
VVOS
Q4 25
$2.8M
$-5.3M
Q3 25
$-3.2M
$-4.2M
Q2 25
$-3.8M
$-4.3M
Q1 25
$-3.6M
$-3.9M
Q4 24
$-6.5M
$-3.1M
Q3 24
$-7.7M
$-4.4M
Q2 24
$-1.1M
$-3.1M
Q1 24
$-1.5M
$-2.7M
FCF Margin
INVE
INVE
VVOS
VVOS
Q4 25
45.8%
-139.7%
Q3 25
-64.5%
-62.6%
Q2 25
-75.8%
-111.6%
Q1 25
-68.0%
-129.9%
Q4 24
-97.7%
-84.0%
Q3 24
-118.2%
-113.4%
Q2 24
-16.7%
-76.7%
Q1 24
-23.0%
-78.0%
Capex Intensity
INVE
INVE
VVOS
VVOS
Q4 25
3.3%
40.0%
Q3 25
7.0%
1.2%
Q2 25
5.0%
20.2%
Q1 25
5.7%
4.0%
Q4 24
9.3%
4.5%
Q3 24
7.7%
5.0%
Q2 24
2.0%
1.5%
Q1 24
3.5%
4.4%
Cash Conversion
INVE
INVE
VVOS
VVOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
-0.08×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

INVE
INVE

Other$3.4M55%
Europe And Middle East$2.2M36%
Asia Pacific$575.0K9%

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons